Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Age | One or more doses | UTD** |
|---|---|---|
| 13 years | 71.1% | 50.5% |
| 14 years | 77% | 60.6% |
| 15 years | 77.7% | 64.6% |
| 16 years | 82.9% | 69.6% |
| 17 years | 81.7% | 68.1% |
| Total | 78.2% | 62.9% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
August 2025
More information
Region
United States
Survey time period
2024
Number of respondents
16,325 adolescents
Age group
13-17 years
Special properties
parents and guardians of adolescents
Method of interview
Telephone interview
Supplementary notes
*HPV vaccine, nine–valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV).
** UTD = up-to-date. HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least 5 months minus 4 days elapsed between the
first and second dose. This update to the HPV recommendation occurred in December of 2016.
Citation formats
